TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable | March 21, 2017 | Dave Fornell

March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of...

iFR, iFR vs. FFR, ACC late breaking trial, iFR-SWEDEHEART, DEFINE-FLAIR, Justin E. Davies,

Matthias Götberg, principal investigator for the iFR-SWEDEHEART study, and Justin E. Davies, lead investigator for the DEFINE-FLAIR trial, share key points of their study with DAIC editor Dave Fornell at ACC.17. The trials showed iFR is equal in outcomes to FFR in assessing coronary lesions. 

Feature | FFR Technologies | March 20, 2017

March 20, 2017 — For patients experiencing angina (chest pain) or a heart attack, instantaneous wave-free ratio (iFR...

Michael Reardon, SURTAVI, TAVR equals surgery in intermediate risk patients

SURTAVI Trial principal investigator Michael Reardon presents the data as a lake-breaker at ACC 2017. 

News | Heart Valve Technology | March 17, 2017 | Dave Fornell

March 17, 2017 - Transcatheter aortic valve replacement (TAVR) was found to be noninferior to surgical aortic valve...

interventional cardiology, cath lab videos
Feature | Cath Lab | March 07, 2017

Here is a compilation of some of DAIC's recent video coverage of new interventional cardiology device technologies...

Videos | Stents Bifurcation | March 06, 2017

This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent. It became the first...

tryton side branch stent, dedicated coronary side branch stent

The Tryton Side Branch Stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel.

Technology | Stents Bifurcation | March 06, 2017

March 6, 2017 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for the Tryton...

CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017

March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...

Claret Medical Sentinel Cerebral Protection System (CPS), FDA, TAVR embolic protection, transcatheter aortic valve replacement (TAVR).
News | Heart Valve Technology | February 28, 2017

February 28, 2017 — A U.S. Food and Drug Administration (FDA) panel has recommended market clearance for the Claret...

transradial approach, same-day cardiac procedures, radial access, $300 million annual savings, JACC Cardiovascular Interventions study
News | Radial Access | February 22, 2017

February 22, 2017 — If hospitals can perform more...

heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR | February 15, 2017 | Dave Fornell

In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve...

Blog | Stents | February 13, 2017

Stents were the key focus of interventional cardiology for more than 20 years, but the focus has changed in recent...

 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure | February 10, 2017 | Dave Fornell

 

In the past few years there have been a number of device therapies developed to treat heart failure (HF)....

Blog | January 30, 2017

DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys...

Overlay Init